Trial Profile
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; CNS cancer; Colorectal cancer; Small cell lung cancer; Solid tumours; Uterine cancer
- Focus Therapeutic Use
- Acronyms CheckMate 848
- Sponsors Bristol-Myers Squibb
- 22 Aug 2023 Status changed from active, no longer recruiting to completed.
- 13 Apr 2022 Results of an analysis assessed the tissue- and plasma-derived tumor mutational burden and genomic alterations of interest presented at the 113th Annual Meeting of the American Association for Cancer Research
- 13 Apr 2022 Results of the interim and final analyses for the tTMB-H and bTMB-H cohorts respectively presented at the 113th Annual Meeting of the American Association for Cancer Research